# PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis

> **NCT01212770** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 505 (actual)

## Conditions studied

- Psoriatic Arthritis

## Interventions

- **DRUG:** Apremilast 20mg
- **DRUG:** Apremilast 30mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01212770
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09-30
- **Primary completion:** 2012-08-21
- **Final completion:** 2017-02-09
- **Target enrollment:** 505 (ACTUAL)
- **Last updated:** 2020-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01212770

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01212770, "PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01212770. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*